Survey: Compliance Programs Don’t Hurt Bottom Line, But Face Other Hurdles
This article was originally published in The Gray Sheet
Nine out of 10 device and diagnostic firms responding to a survey say implementing a compliance program based on the 1AdvaMed Code of Ethics did not hurt their company's bottom line, including 10% who say their compliance program increased revenue
You may also be interested in...
The House Committee on Oversight and Government Reform is requesting information on the off-label use and marketing of drug-eluting stents
A new survey suggests that medical device firms are complying with industry standards written to prevent fraudulent sales and marketing practices. Roughly 75% of surveyed companies said they post their compliance programs on the company website
Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.